Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMABFree Report) in a research note published on Monday, RTT News reports. The firm currently has a $18.00 price target on the stock, up from their prior price target of $12.00.

Separately, HC Wainwright reiterated a buy rating and issued a $11.00 target price on shares of Y-mAbs Therapeutics in a report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of Hold and an average price target of $12.50.

Read Our Latest Report on Y-mAbs Therapeutics

Y-mAbs Therapeutics Stock Up 9.5 %

Shares of Y-mAbs Therapeutics stock opened at $14.36 on Monday. The business’s fifty day simple moving average is $8.92 and its 200-day simple moving average is $6.66. Y-mAbs Therapeutics has a 52 week low of $2.70 and a 52 week high of $14.49.

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) last posted its earnings results on Monday, November 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 20.75% and a negative return on equity of 18.28%. The company had revenue of $20.45 million during the quarter, compared to analyst estimates of $20.56 million. As a group, sell-side analysts expect that Y-mAbs Therapeutics will post -0.67 EPS for the current year.

Insider Activity

In related news, insider Thomas Gad sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $5.30, for a total transaction of $397,500.00. Following the sale, the insider now directly owns 490,032 shares of the company’s stock, valued at approximately $2,597,169.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Johan Wedell-Wedellsborg acquired 62,516 shares of the firm’s stock in a transaction dated Monday, November 27th. The stock was acquired at an average price of $5.49 per share, for a total transaction of $343,212.84. Following the purchase, the director now owns 4,342,721 shares of the company’s stock, valued at approximately $23,841,538.29. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Thomas Gad sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $5.30, for a total transaction of $397,500.00. Following the sale, the insider now owns 490,032 shares in the company, valued at $2,597,169.60. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 223,399 shares of company stock valued at $1,413,939 and sold 175,000 shares valued at $1,057,000. Insiders own 21.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Polar Capital Holdings Plc raised its holdings in shares of Y-mAbs Therapeutics by 108.9% in the 1st quarter. Polar Capital Holdings Plc now owns 2,877,671 shares of the company’s stock valued at $34,187,000 after purchasing an additional 1,500,000 shares in the last quarter. Millennium Management LLC lifted its holdings in Y-mAbs Therapeutics by 4,676.0% during the 4th quarter. Millennium Management LLC now owns 1,128,702 shares of the company’s stock worth $5,508,000 after buying an additional 1,105,069 shares during the last quarter. State Street Corp boosted its position in shares of Y-mAbs Therapeutics by 58.5% during the 1st quarter. State Street Corp now owns 2,308,782 shares of the company’s stock worth $27,428,000 after acquiring an additional 852,112 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $2,343,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Y-mAbs Therapeutics during the 4th quarter worth about $2,193,000. Hedge funds and other institutional investors own 45.45% of the company’s stock.

Y-mAbs Therapeutics Company Profile

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Read More

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.